Effects of Sepiapterin Supplementation and NOS Inhibition on Glucocorticoid-Induced Hypertension

被引:10
|
作者
Thida, Mya [1 ]
Earl, John [2 ]
Zhao, Yan [3 ]
Wang, Hans [1 ]
Tse, Chi S. [1 ]
Vickers, Janine J. [1 ]
Sutton, Matthew [1 ]
Ong, Sharon L. H. [1 ]
Mori, Trevor A. [3 ]
Croft, Kevin D. [3 ]
Whitworth, Judith A. [1 ]
Zhang, Yi [1 ]
机构
[1] Australian Natl Univ, John Curtin Sch Med Res, High Blood Pressure Res Unit, Canberra, ACT 2601, Australia
[2] Childrens Hosp Westmead, Sydney, NSW, Australia
[3] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
关键词
blood pressure; endothelial nitric oxide synthase; glucocorticoid; hypertension; N-nitro-L-arginine (NOLA); rat; sepiapterin; NITRIC-OXIDE SYNTHASE; DEXAMETHASONE-INDUCED HYPERTENSION; HORMONE-INDUCED HYPERTENSION; ADRENOCORTICOTROPIN-INDUCED HYPERTENSION; GTP-CYCLOHYDROLASE-I; L-ARGININE PREVENTS; BLOOD-PRESSURE; DOWN-REGULATION; RAT; TETRAHYDROBIOPTERIN;
D O I
10.1038/ajh.2010.27
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND Glucocorticoid-induced hypertension is associated with imbalance between nitric oxide (NO) and superoxide. One of the pathways that causes this imbalance is endothelial NO synthase (eNOS) uncoupling. In the present study, adrenocorticotrophic hormone (ACTH)- and dexamethasone-treated rats were further treated with sepiapterin, a precursor of tetrahydrobiopterin, or N-nitro-L-arginine (NOLA), an inhibitor of NOS, to investigate the role of eNOS uncoupling in glucocorticoid-induced hypertension. METHODS Male Sprague-Dawley (SD) rats (n = 7-13/group) were treated with either sepiapterin (5 mg/kg/day, IP) or saline (sham) 4 days before and during ACTH (0.2 mg/kg/day, SC), dexamethasone (0.03 mg/kg/day, SC), or saline treatment. NOLA (0.4 mg/ml in drinking water) was given to rats 4 days before and during dexamethasone treatment. Systolic blood pressure (SBP) was measured by the tail-cuff method. RESULTS Both ACTH (116 +/- 2 to 135 +/- 3 mm Hg (mean s.e.m.), P < 0.001) and dexamethasone (114 +/- 4 to 133 +/- 3 mm Hg, P < 0.0005) increased SBP. Sepiapterin alone did not alter SBP. Sepiapterin did not prevent ACTH- (129 +/- 4 mm Hg, NS) or dexamethasone-induced hypertension (135 +/- 3 mm Hg, NS), although plasma total biopterin concentrations were increased. NOLA increased SBP in rats prior to dexamethasone or saline treatment. NOLA further increased SBP in both saline (133 +/- 4 to 157 +/- 3 mm Hg, P < 0.05) and dexamethasone-treated rats (135 5 to 170 6 mm Hg, P < 0.05). ACTH and dexamethasone increased plasma F-2-isoprostane concentrations. Neither sepiapterin nor NOLA significantly affected this marker of oxidative stress. CONCLUSION Sepiapterin did not prevent ACTH- or dexamethasone-induced hypertension. NOLA exacerbated dexamethasone-induced hypertension. These data suggest that eNOS uncoupling does not play a major role in the genesis of glucocorticoid-induced hypertension in the rat.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 50 条
  • [31] Glucocorticoid-induced osteoporosis: An update on effects and management
    Buehring, Bjoern
    Viswanathan, Ravi
    Binkley, Neil
    Busse, William
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (05) : 1019 - 1030
  • [32] Glucocorticoid-induced osteoclastogenesis is compromised in glucocorticoid-induced AVN in SLE patients
    Oh, Brian
    Kaneko, Kaichi
    Chen, Hao
    Krez, Alexandra
    Heilbronner, Alison
    Zeng, Steven
    Park, Peter Sang
    Lee, Ye-Ji
    Fujii, Takayuki
    Kim, Haemin
    Mun, Sehwan
    Bae, Seyeon
    Pannellini, Tania
    Lane, Joseph
    Hansen, Derek
    Mintz, Douglas
    Bockman, Richard
    Stein, Emily
    Park-Min, Kyung-Hyun
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 35 - 35
  • [33] Glucocorticoid-induced osteoclastogenesis is compromised in glucocorticoid-induced AVN in SLE patients
    Oh, Brian
    Kaneko, Kaichi
    Chen, Hao
    Krez, Alexandra
    Heilbronner, Alison
    Zeng, Steven
    Park, Peter Sang
    Lee, Ye-Ji
    Fujii, Takayuki
    Kim, Haemin
    Mun, Sehwan
    Bae, Seyeon
    Pannellini, Tania
    Lane, Joseph
    Hansen, Derek
    Mintz, Douglas
    Bockman, Richard
    Stein, Emily
    Park-Min, Kyung-Hyun
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 250 - 250
  • [34] The serum- and glucocorticoid-induced kinase in DOCA–salt hypertension
    Friedrich C. Luft
    Journal of Molecular Medicine, 2006, 84 : 709 - 711
  • [35] Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize
    Yorio, Thomas
    Patel, Gaurang C.
    Clark, Abbot F.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2020, 15 (03) : 145 - 157
  • [36] ENHANCED RENIN SECRETION IN ADRENALECTOMIZED RATS WITH GLUCOCORTICOID-INDUCED HYPERTENSION
    KASSER, A
    WAEBER, B
    NUSSBERGER, J
    BURRIS, J
    BRUNNER, HR
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1985, 7 (11) : 1619 - 1628
  • [37] Mouse strain differences in development of glucocorticoid-induced ocular hypertension
    Patel, Pinkal D.
    Patel, Gaurang
    Geisert, Eldon E.
    Millar, J. Cameron
    Clark, Abbot F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [38] Microvascular endothelial cell death in glucocorticoid-induced hypertension.
    Vogt, CJ
    Zweifach, BW
    SchmidSchonbein, GW
    FASEB JOURNAL, 1997, 11 (03): : 2706 - 2706
  • [39] Effects of Resveratrol on Hypertension Developing by NOS inhibition
    Aksulu, Hakki Engin
    Silan, Coskun
    Gungor, Buket
    Akdur, Secil
    ACTA PHYSIOLOGICA, 2015, 215 : 77 - 77
  • [40] Glucocorticoid-induced osteoporosis
    Fine, JB
    Fine, RM
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1998, 37 (05) : 346 - 347